Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers
Di Yin,Yiye Zhong,Sikai Ling,Sicong Lu,Xiaoyuan Wang,Zhuofan Jiang,Jie Wang,Yao Dai,Xiaolong Tian,Qijing Huang,Xingbo Wang,Junsong Chen,Ziying Li,Yang Li,Zhijue Xu,Hewei Jiang,Yuqing Wu,Yi Shi,Quanjun Wang,Jianjiang Xu,Wei Hong,Heng Xue,Hang Yang,Yan Zhang,Lintai Da,Ze-guang Han,Sheng-ce Tao,Ruijiao Dong,Tianlei Ying,Jiaxu Hong,Yujia Cai
DOI: https://doi.org/10.1038/s41551-024-01208-4
IF: 28.1
2024-05-08
Nature Biomedical Engineering
Abstract:Messenger RNA vaccines lack specificity for dendritic cells (DCs)—the most effective cells at antigen presentation. Here we report the design and performance of a DC-targeting virus-like particle pseudotyped with an engineered Sindbis-virus glycoprotein that recognizes a surface protein on DCs, and packaging mRNA encoding for the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or for the glycoproteins B and D of herpes simplex virus 1. Injection of the DC-targeting SARS-CoV-2 mRNA vaccine in the footpad of mice led to substantially higher and durable antigen-specific immunoglobulin-G titres and cellular immune responses than untargeted virus-like particles and lipid–nanoparticle formulations. The vaccines also protected the mice from infection with SARS-CoV-2 or with herpes simplex virus 1. Virus-like particles with preferential uptake by DCs may facilitate the development of potent prophylactic and therapeutic vaccines.
engineering, biomedical